R.H. Bluestein & Co’s Eli Lilly LLY Stock Holding History

R.H. Bluestein & Co’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$35.3M	Buy	109,022 +45,038	+70%	+$14.3M	2.19%	14
2022 Q2	$20.7M	Buy	+63,984	New	+$19.2M	1.27%	22
2019 Q4	–	Sell	-233,919	Closed	-$26.2M	–	354
2019 Q3	$26.2M	Buy	233,919 +3,909	+2%	+$435K	1.47%	33
2019 Q2	$25.5M	Buy	230,010 +18,359	+9%	+$2.16M	1.36%	35
2019 Q1	$27.5M	Buy	211,651 +144,669	+216%	+$17.6M	1.5%	28
2018 Q4	$7.75M	Buy	+66,982	New	+$7.48M	0.61%	38
2016 Q4	–	Sell	-5,595	Closed	-$449K	–	315
2016 Q3	$449K	Sell	5,595 -27,180	-83%	-$2.18M	0.03%	121
2016 Q2	$2.58M	Buy	+32,775	New	+$2.47M	0.2%	41
2014 Q3	–	Sell	-7,550	Closed	-$469K	–	372
2014 Q2	$469K	Sell	7,550 -450	-6%	-$26.8K	0.03%	217
2014 Q1	$471K	Buy	+8,000	New	+$446K	0.03%	198

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

R.H. Bluestein & Co's LLY Position: Q3 2022 in Review

R.H. Bluestein & Co increased its Eli Lilly (LLY) stake by 70% in Q3 2022, buying an estimated $14.3M and bringing the position to 109,022 shares worth $35.3M. The position accounts for 2.19% of the portfolio, ranked #14.

R.H. Bluestein & Co first reported a position in LLY in Q1 2014 and has held it in 10 quarters since. 2,484 funds tracked by Wall St. Rank hold LLY as of Q3 2022.

R.H. Bluestein & Co held 109,022 shares of Eli Lilly worth $35.3M as of Q3 2022.
R.H. Bluestein & Co bought 45,038 Eli Lilly shares in Q3 2022, an estimated $14.3M.
Eli Lilly made up 2.19% of R.H. Bluestein & Co's portfolio in Q3 2022, its #14 holding.
R.H. Bluestein & Co first reported a position in Eli Lilly in Q1 2014 and has held it in 10 quarters since.
2,484 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2022.

Based on R.H. Bluestein & Co's 13F filing for Q3 2022, filed 14 Nov 2022.